Kuala lumpur: SINTX Technologies Inc (SINTX) has signed a supply agreement with Evonik Corporation (EVONIK) to manufacture its proprietary silicon nitride-PEEK (SiN/PEEK) compound for artificial intelligence (AI)-assisted additive manufacturing of patient-specific implants.

According to BERNAMA News Agency, under the agreement, EVONIK will produce the SiN/PEEK compound at commercial scale to SINTX’s specifications. This will enable the immediate production of AI-designed, 3D-printed implants using SINTX’s existing United States-based production facility.

SINTX has already received physician requests for humanitarian-use vertebral body replacement implants for orthopaedic and neurosurgical oncology cases. The company also plans to use the compound in regulatory submissions for both patient-matched and traditionally manufactured devices.

SINTX Chairman, President, and Chief Executive Officer, Eric K. Olson stated that the collaboration unites EVONIK’s polymer expertise with SINTX’s biomaterial strengths to deliver next-generation implants with antipathogenic, osteogenic, and imaging advantages over standard PEEK.

EVONIK head of Medical Devices and Systems market segment, Marc Knebel, highlighted that the partnership aims to ensure consistent quality, supply reliability, and scalability as both companies expand data generation for future device applications.

The SiN/PEEK blend is engineered for antipathogenic surface behaviour, osteogenic support, improved visualisation, and design freedom using AI-assisted additive manufacturing, which are key attributes for complex, high-risk procedures.

Both parties expect to make the compound available to other qualified manufacturers for advanced implant applications. Headquartered in Salt Lake City, Utah, SINTX is an advanced ceramics and biomaterials company that develops, manufactures, and commercialises silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications.